New radiation approach aims to control inoperable rectal cancer recurrence
NCT ID NCT07297004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether a high-precision radiation technique called stereotactic body radiation therapy (SBRT) can help control locally recurrent rectal cancer that cannot be surgically removed. The study will enroll 40 adults aged 18-75 with unresectable tumors and no distant spread. The main goal is to see if SBRT can improve the chance that the cancer does not grow for at least one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this could offer a non-surgical option to control tumor growth in patients with recurrent rectal cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase study with only 40 participants and no comparison group. The expected improvement in local control is modest (from 20% to 40%), and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY RECURRENT RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.